Product image
Product image
InVivoPlus anti-mouse 4-1BB (CD137)
BP0169
Overview
- SupplierBio X Cell
- Product NameInVivoPlus anti-mouse 4-1BB (CD137)
- Delivery Days Customer7
- ApplicationsOther Application
- CertificationResearch Use Only
- ClonalityMonoclonal
- Clone IDLOB12.3
- Concentration4-11 mg/ml
- HostRat
- IsotypeIgG1
- Scientific DescriptionThe LOB12.3 monoclonal antibody reacts with mouse 4-1BB, a TNF receptor superfamily member also known as CD137. 4-1BB is a 39 kDa transmembrane protein expressed by T lymphocytes, NK cells, dendritic cells, granulocytes, and mast cells. Upon binding its ligand 4-1BBL, 4-1BB provides costimulatory signals to both CD4 and CD8 T cells through the activation of NF- κB, c-Jun and p38 downstream pathways. The importance of the 4-1BB pathway has been underscored in a number of diseases, including cancer. Agonistic anti-4-1BB antibodies have been reported to induce T cell mediated antitumor immunity. The LOB12.3 antibody is an agonistic antibody that has been shown to stimulate 4-1BB signaling and delay tumor growth in vivo when administered in combination with immune checkpoint inhibitors.
- ReactivityMouse
- Storage Instruction2°C to 8°C
- UNSPSC12352203
References
- Optimization of 4-1BB antibody for cancer immunotherapy by balancing agonistic strength with FcgammaR affinity. Qi X et al., 2019 May 20, Nat CommunRead more
- Unique potential of 4-1BB agonist antibody to promote durable regression of HPV+ tumors when combined with an E6/E7 peptide vaccine. Bartkowiak T et al., 2015 Sep 22, Proc Natl Acad Sci U S ARead more
- Curing mice with large tumors by locally delivering combinations of immunomodulatory antibodies. Dai M et al., 2015 Mar 1, Clin Cancer ResRead more
- Anaphylaxis caused by repetitive doses of a GITR agonist monoclonal antibody in mice. Murphy JT et al., 2014 Apr 3, BloodRead more
- Combinatorial PD-1 blockade and CD137 activation has therapeutic efficacy in murine cancer models and synergizes with cisplatin. Wei H et al., 2013, PLoS OneRead more
- Combined TIM-3 blockade and CD137 activation affords the long-term protection in a murine model of ovarian cancer. Guo Z et al., 2013 Sep 17, J Transl MedRead more
- Long-lasting complete regression of established mouse tumors by counteracting Th2 inflammation. Dai M et al., 2013 May, J ImmunotherRead more
- CD4+ T cells develop antiretroviral cytotoxic activity in the absence of regulatory T cells and CD8+ T cells. Manzke N et al., 2013 Jun, J VirolRead more
- Localized immunotherapy via liposome-anchored Anti-CD137 + IL-2 prevents lethal toxicity and elicits local and systemic antitumor immunity. Kwong B et al., 2013 Mar 1, Cancer ResRead more
- Combination CTLA-4 blockade and 4-1BB activation enhances tumor rejection by increasing T-cell infiltration, proliferation, and cytokine production. Curran MA et al., 2011 Apr 29, PLoS OneRead more
